Journal
CLINICAL CANCER RESEARCH
Volume 16, Issue 21, Pages 5339-5350Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-1638
Keywords
-
Categories
Funding
- Ministry of Health Welfare & Family Affairs, Republic of Korea [A070001]
- Ministry of Health Welfare, Korea [01-PJ10-PG6-01GN16-0005]
- Princess Margaret Hospital Foundation, Toronto, ON, Canada
Ask authors/readers for more resources
Purpose: The present study analyzed treatment outcomes of imatinib therapy by interindividual genetic variants in candidate biological pathways of chronic myeloid leukemia (CML) such as apoptosis, angiogenesis, IFN-gamma signaling pathways, or drug transport/metabolism of imatinib. Experimental Design: Peripheral blood DNAs were genotyped for 79 single nucleotide polymorphism markers involved in the pathways of apoptosis, angiogenesis, myeloid cell growth, xenobiotic metabolism, WT1 signaling, IFN signaling, and others in CML patients who were included in discovery (n = 229, Canada) and validation cohorts (n = 187, Korea). Results: We found several genotypes associated with complete cytogenetic response: IFNG (rs1861494, rs2069705), FASL (rs763110), FAS (rs2234767, rs2234978), VEGFR2 (rs1531289), and WT1 (rs2234590); with major molecular response: IFNG (rs1861494, rs2069705), BIRC5 (rs9904341), FAS (rs2234978), and ABCG2 (rs2231142); with loss of response: IFNG (rs2069705), IFNGR2 (rs9808753), BIRC5 (rs9904341), and ORM (rs3182041); and with treatment failure: IFNG (rs2069705), JAK3 (rs3212713), and ORM (rs3182041). External validation for the above significant genotypes confirmed that the IFNG genotype (rs2069705) was predictive of complete cytogenetic response (hazard ratio, 2.17; P < 0.001) and major molecular response (hazard ratio, 1.96; P = 0.0001) in validation cohorts of Korean ethnicity. Conclusions: The IFNG genotype was predictive for response to imatinib therapy, suggesting potential involvement of the IFN-gamma signaling pathway in the mechanism of action of imatinib in CML. Clin Cancer Res; 16(21); 5339-50. (C) 2010 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available